Abbott reports fourth-quarter sales that miss analysts’ estimates.

Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%. Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80 and first-quarter 2026 ...

The Medical Devices business remained a standout performer at Abbott, with Q4 sales up 12.3% to $5.68 billion. Abbott ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...

Abbott Laboratories forecast a 1Q profit that was lower than Wall Street expected and missed 4Q sales estimates after its ...

Abbott Laboratories (ABT) on Thursday reported fourth-quarter net income of $1.78 billion. The Abbott Park, Illinois-based ...

Buy Abbott: defensive compounder with recurring cash flow. Libre diabetes devices drive growth; 2025 guidance reaffirmed. Know more about ABT stock here.

Abbott Laboratories and Decom will concentrate on competing in the huge market of potential continuous glucose monitor technology and put any patent disputes behind them for 10 years. North ...

NEW YORK -- Abbott Laboratories on Monday said it would pay $6.6 billion for the pharmaceutical business of Belgian chemicals maker Solvay in a move to further expand internationally and add to its ...

Abbott’s latest CE mark for its TactiFlex Duo system was based on a clinical trial conducted in the European Union, United ...